A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 May 2024 According to a Lytix Biopharma media release, new update will be given during H2 2024.
29 Feb 2024 Interim results from 20 melanoma patients, presented in a Lytix Biopharma media release.
08 Nov 2023 According to a Lytix Biopharma media release, Later in the month, on 23 Nov, Dr Rekdal will give a presentation at the Redeye Life Science Day 2023 in Stockholm. There he will answer questions about the Company's latest positive developments, in particular, the preliminary Phase II data recently presented at ESMO.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com